Ratings HYUGA PRIMARY CARE Co.,Ltd.

Equities

7133

JP3794570006

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-20 am EDT			5-day change	1st Jan Change
1,663 ^JPY	-0.95%		-4.64%	-12.06%

2023	HYUGA PRIMARY CARE Co.,Ltd. agreed to acquire MedicalMind Co., Ltd. from Hajime Urashima for ¥500 million.	CI
2023	Tranche Update on HYUGA PRIMARY CARE Co.,Ltd.'s Equity Buyback Plan announced on September 15, 2023.	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Sales forecast by analysts have been recently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.

Weaknesses

The company appears highly valued given the size of its balance sheet.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Drug Retailers

	1st Jan change	Capi.	ESG Refinitiv
HYUGA PRIMARY CARE CO.,LTD.	-12.06%	76.68M	-
WALGREENS BOOTS ALLIANCE, INC.	-31.16%	15.68B	B-
JD HEALTH INTERNATIONAL INC.	-20.59%	12.39B	B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-21.23%	6.74B	B
MATSUKIYOCOCOKARA & CO.	-6.15%	6.29B	C+
YIFENG PHARMACY CHAIN CO., LTD.	+10.76%	6.26B	C
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+70.00%	4.95B	C
NAHDI MEDICAL COMPANY	-2.48%	4.66B	D-
CLICKS GROUP LIMITED	-5.58%	4.03B	B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-9.24%	3.62B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes